<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
 <record>
  <leader>     caa a22        4500</leader>
  <controlfield tag="001">469074280</controlfield>
  <controlfield tag="003">CHVBK</controlfield>
  <controlfield tag="005">20180323132931.0</controlfield>
  <controlfield tag="007">cr unu---uuuuu</controlfield>
  <controlfield tag="008">170328e19920701xx      s     000 0 eng  </controlfield>
  <datafield tag="024" ind1="7" ind2="0">
   <subfield code="a">10.1007/BF01741789</subfield>
   <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
   <subfield code="a">(NATIONALLICENCE)springer-10.1007/BF01741789</subfield>
  </datafield>
  <datafield tag="245" ind1="0" ind2="0">
   <subfield code="a">Tissue distribution of adoptively transferred adherent lymphokine-activated killer cells assessed by different cell labels</subfield>
   <subfield code="h">[Elektronische Daten]</subfield>
   <subfield code="c">[P. Basse, R. Herberman, M. Hokland, R. Goldfarb]</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
   <subfield code="a">Summary: Assessment of the tissue distribution of adoptively transferred adherent lymphokine-activated killer A-LAK) cells by use of51Cr indicated that these effector cells, after an initial phase in the lungs, distributed in high numbers to liver and spleen (30% and 10% of injected dose, respectively). However, when this experiment was repeated with125IdUrd as cell label, fewer than 2% and 0.5% of the injected cells distributed into liver and spleen respectively. To analyse this discrepancy, we compared the tissue distribution of51Cr- and125IdUrd-labelled A-LAK cells with that indicated by alternative direct visual methods for identification of the injected cells, such as fluorescent dyes (rhodamine and H33342) or immunohistochemical staining of asialo-GM1-positive cells. The number of i. v. injected A-LAK cells found in the liver by all visual methods ranged from 1% to 5% of the injected dose, supporting the data obtained with125IdUrd, whereas 25%-30% of the51Cr label was consistently found in this organ. Autoradiography of the liver 24 h after i. v. injection of51Cr-labelled cells revealed a background activity that was four- to fivefold higher than the control level, indicating substantial non-specific accumulation in the liver of51Cr released from A-LAK cells. We conclude that51Cr cannot be reliably used in investigations of cell traffic to the liver because of non-specific accumulation of the51Cr label, particularly in this organ. In contrast, labelling with125IdUrd or rhodamine and immunohistochemical staining of asialo-GM1-positive cells appear to be reliable and essentially equivalent methods for investigations of the fate of adoptively transferred A-LAK cells. Using these methods, we found that only few A-LAK cells redistribute to the liver upon i. v., i. e. systemic, injection, whereas 40%-50% of locally (intraportally) injected A-LAK cells remain in the liver for at least 24 h.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
   <subfield code="a">Springer-Verlag, 1992</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">LAK migration</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Asialo-GM1 antibody</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Fluorescence</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Rhodamine</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Hoechst 33342</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Basse</subfield>
   <subfield code="D">P.</subfield>
   <subfield code="u">Pittsburgh Cancer Institute and Departments of Pathology and Medicine, University of Pittsburgh, 15 213, Pittsburgh, PA, USA</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Herberman</subfield>
   <subfield code="D">R.</subfield>
   <subfield code="u">Pittsburgh Cancer Institute and Departments of Pathology and Medicine, University of Pittsburgh, 15 213, Pittsburgh, PA, USA</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Hokland</subfield>
   <subfield code="D">M.</subfield>
   <subfield code="u">Institute of Medical Microbiology, University of Aarhus, DK-8000, Aarhus C, Denmark</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Goldfarb</subfield>
   <subfield code="D">R.</subfield>
   <subfield code="u">Pittsburgh Cancer Institute and Departments of Pathology and Medicine, University of Pittsburgh, 15 213, Pittsburgh, PA, USA</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
   <subfield code="t">Cancer Immunology, Immunotherapy</subfield>
   <subfield code="d">Springer-Verlag</subfield>
   <subfield code="g">34/4(1992-07-01), 221-227</subfield>
   <subfield code="x">0340-7004</subfield>
   <subfield code="q">34:4&lt;221</subfield>
   <subfield code="1">1992</subfield>
   <subfield code="2">34</subfield>
   <subfield code="o">262</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
   <subfield code="u">https://doi.org/10.1007/BF01741789</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="908" ind1=" " ind2=" ">
   <subfield code="D">1</subfield>
   <subfield code="a">research-article</subfield>
   <subfield code="2">jats</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">856</subfield>
   <subfield code="E">40</subfield>
   <subfield code="u">https://doi.org/10.1007/BF01741789</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Basse</subfield>
   <subfield code="D">P.</subfield>
   <subfield code="u">Pittsburgh Cancer Institute and Departments of Pathology and Medicine, University of Pittsburgh, 15 213, Pittsburgh, PA, USA</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Herberman</subfield>
   <subfield code="D">R.</subfield>
   <subfield code="u">Pittsburgh Cancer Institute and Departments of Pathology and Medicine, University of Pittsburgh, 15 213, Pittsburgh, PA, USA</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Hokland</subfield>
   <subfield code="D">M.</subfield>
   <subfield code="u">Institute of Medical Microbiology, University of Aarhus, DK-8000, Aarhus C, Denmark</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Goldfarb</subfield>
   <subfield code="D">R.</subfield>
   <subfield code="u">Pittsburgh Cancer Institute and Departments of Pathology and Medicine, University of Pittsburgh, 15 213, Pittsburgh, PA, USA</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">773</subfield>
   <subfield code="E">0-</subfield>
   <subfield code="t">Cancer Immunology, Immunotherapy</subfield>
   <subfield code="d">Springer-Verlag</subfield>
   <subfield code="g">34/4(1992-07-01), 221-227</subfield>
   <subfield code="x">0340-7004</subfield>
   <subfield code="q">34:4&lt;221</subfield>
   <subfield code="1">1992</subfield>
   <subfield code="2">34</subfield>
   <subfield code="o">262</subfield>
  </datafield>
  <datafield tag="900" ind1=" " ind2="7">
   <subfield code="a">Metadata rights reserved</subfield>
   <subfield code="b">Springer special CC-BY-NC licence</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="898" ind1=" " ind2=" ">
   <subfield code="a">BK010053</subfield>
   <subfield code="b">XK010053</subfield>
   <subfield code="c">XK010000</subfield>
  </datafield>
  <datafield tag="949" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="F">NATIONALLICENCE</subfield>
   <subfield code="b">NL-springer</subfield>
  </datafield>
 </record>
</collection>
